
https://www.science.org/content/blog-post/per-fits-and-starts-ad-astra
# Per Fits and Starts, Ad Astra (August 2003)

## 1. SUMMARY

This is a personal reflective essay by a medicinal chemist or drug discovery researcher working in the pharmaceutical industry, not a commentary specifically about biotechnology. The author describes their internal conflict around a chemistry idea they've been developing intermittently. They explain their prior hesitation to share details due to intellectual property constraints from their employer and personal concerns about scientific priority. The author reflects on the tension between the demanding, structured nature of industrial drug discovery work and the need for unstructured "staring-out-the-window time" to generate creative ideas. They express self-consciousness about their "jerky bursts" approach to research compared to more disciplined colleagues, while also critiquing how relentless industry work schedules can stifle innovation. As the essay closes, the author reveals they finally have an opportunity to advance their concept because it aligns with their lab's official project, expressing both hope and anxiety about testing their "favorite ideas" and discovering whether they actually work.

## 2. HISTORY

This article cannot be meaningfully analyzed for subsequent "history" in the way the template intends. The essay is a personal blog-style reflection about internal thought processes and work habits, not a discussion of specific scientific developments, companies, technologies, or policy changes. It contains no concrete biotech industry claims, drug candidates, clinical trials, regulatory events, or business developments that could be tracked over time. The author explicitly refuses to disclose what their chemistry idea actually is, making verification impossible.

The pharmaceutical industry context the author describes—IP ownership by employers, tension between productivity demands and creative time, the reality that most drug discovery ideas fail—remains largely unchanged in the two decades since publication.

## 3. PREDICTIONS

The article contains no predictions about biotechnology, drug development outcomes, industry trends, or clinical/scientific developments that could be evaluated against later events. The author's primary forward-looking statements are personal and immediate: hoping to "ignore all distractions" and complete lab work "the week after that should see the first runs of the real thing." These are timeline intentions for personal experiments, not predictions about the field.

## 4. INTEREST

Rating: **2/10**

This is a personal blog post about work habits and psychological aspects of drug discovery research, not an informative article about biotechnology developments. While it offers authentic insight into industrial research culture, it provides no concrete scientific information, business analysis, or industry developments that would make it valuable for understanding biotech progress.

## 5. ASSESSMENT

The article appears to be a personal blog entry from "In the Pipeline," a well-known pharmaceutical industry blog written by Derek Lowe, rather than a substantive biotechnology commentary. While it captures real aspects of drug discovery culture and the psychology of researchers, it doesn't function as the kind of analytical commentary the template was designed for. The template appears better suited for articles discussing specific biotech technologies, companies, clinical trials, or policy debates that can be factually evaluated with hindsight, rather than personal reflections on work processes.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20030803-per-fits-and-starts-ad-astra.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_